메뉴 건너뛰기




Volumn 61, Issue 1, 2013, Pages 40-44

Type 1 diabetes treatment beyond insulin: Role of GLP-1 analogs

Author keywords

Glp 1; Glucagonlike peptide; Incretin; Liraglutide; Type 1 diabetes

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN; LIRAGLUTIDE;

EID: 84873642385     PISSN: 17088267     EISSN: 17088267     Source Type: Journal    
DOI: 10.2310/JIM.0b013e318279b7d6     Document Type: Review
Times cited : (45)

References (19)
  • 1
    • 25644453616 scopus 로고    scopus 로고
    • Glycemic characteristics in continuously monitored patients with type 1 and type 2 diabetes: Normative values
    • Bode BW, Schwartz S, Stubbs HA, et al. Glycemic characteristics in continuously monitored patients with type 1 and type 2 diabetes: normative values. Diabetes Care. 2005;28:2361-2366.
    • (2005) Diabetes Care. , vol.28 , pp. 2361-2366
    • Bode, B.W.1    Schwartz, S.2    Stubbs, H.A.3
  • 2
    • 65549113825 scopus 로고    scopus 로고
    • Acute hyperinsulinemia raises plasma interleukin-6 in both nondiabetic and type 2 diabetes mellitus subjects, and this effect is inversely associated with body mass index
    • Ruge T, Lockton JA, Renstrom F, et al. Acute hyperinsulinemia raises plasma interleukin-6 in both nondiabetic and type 2 diabetes mellitus subjects, and this effect is inversely associated with body mass index. Metabolism. 2009;58:860-866.
    • (2009) Metabolism. , vol.58 , pp. 860-866
    • Ruge, T.1    Lockton, J.A.2    Renstrom, F.3
  • 3
    • 33746110778 scopus 로고    scopus 로고
    • Hyperandrogenism, insulin resistance and hyperinsulinemia as cardiovascular risk factors in diabetes mellitus
    • Garcia-Romero G, Escobar-Morreale HF. Hyperandrogenism, insulin resistance and hyperinsulinemia as cardiovascular risk factors in diabetes mellitus. Curr Diabetes Rev. 2006;2:39-49.
    • (2006) Curr Diabetes Rev. , vol.2 , pp. 39-49
    • Garcia-Romero, G.1    Escobar-Morreale, H.F.2
  • 4
    • 84873683616 scopus 로고    scopus 로고
    • Insulin resistance/hyperinsulinemia and cancer mortality: The Cremona study at the 15th year of follow-up
    • Perseghin G, Calori G, Lattuada G, et al. Insulin resistance/ hyperinsulinemia and cancer mortality: the Cremona study at the 15th year of follow-up. Acta Diabetol. 2012;49:421-428.
    • (2012) Acta Diabetol. , vol.49 , pp. 421-428
    • Perseghin, G.1    Calori, G.2    Lattuada, G.3
  • 5
    • 77950656511 scopus 로고    scopus 로고
    • Temporal patterns in overweight and obesity in type 1 diabetes
    • Conway B, Miller RG, Costacou T, et al. Temporal patterns in overweight and obesity in type 1 diabetes. Diabet Med. 2010;27: 398-404.
    • (2010) Diabet Med. , vol.27 , pp. 398-404
    • Conway, B.1    Miller, R.G.2    Costacou, T.3
  • 6
    • 0037711693 scopus 로고    scopus 로고
    • Coexistence of type 1 and type 2 diabetes mellitus: Double diabetes?
    • Libman IM, Becker DJ. Coexistence of type 1 and type 2 diabetes mellitus: "double" diabetes? Pediatr Diabetes. 2003;4:110-113.
    • (2003) Pediatr Diabetes. , vol.4 , pp. 110-113
    • Libman, I.M.1    Becker, D.J.2
  • 7
    • 34347332293 scopus 로고    scopus 로고
    • Pramlintide acetate injection for the treatment of type 1 and type 2 diabetes mellitus
    • Singh-Franco D, Robles G, Gazze D. Pramlintide acetate injection for the treatment of type 1 and type 2 diabetes mellitus. Clin Ther. 2007;29:535-562.
    • (2007) Clin Ther. , vol.29 , pp. 535-562
    • Singh-Franco, D.1    Robles, G.2    Gazze, D.3
  • 8
    • 8144228619 scopus 로고    scopus 로고
    • Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in type 1 diabetes mellitus: A 1-year, randomized controlled trial
    • Ratner RE, Dickey R, Fineman M, et al. Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in type 1 diabetes mellitus: a 1-year, randomized controlled trial. Diabet Med. 2004;21:1204-1212.
    • (2004) Diabet Med. , vol.21 , pp. 1204-1212
    • Ratner, R.E.1    Dickey, R.2    Fineman, M.3
  • 9
    • 53849095733 scopus 로고    scopus 로고
    • Glucagon-like peptide receptor agonists and dipeptidyl peptidase-4 inhibitors in the treatment of diabetes: A review of clinical trials
    • Madsbad S, Krarup T, Deacon CF, et al. Glucagon-like peptide receptor agonists and dipeptidyl peptidase-4 inhibitors in the treatment of diabetes: a review of clinical trials. Curr Opin Clin Nutr Metab Care. 2008;11:491-499.
    • (2008) Curr Opin Clin Nutr Metab Care. , vol.11 , pp. 491-499
    • Madsbad, S.1    Krarup, T.2    Deacon, C.F.3
  • 10
    • 67651173077 scopus 로고    scopus 로고
    • Incretin-based therapies for type 2 diabetes mellitus
    • Lovshin JA, Drucker DJ. Incretin-based therapies for type 2 diabetes mellitus. Nat Rev Endocrinol. 2009;5:262-269.
    • (2009) Nat Rev Endocrinol. , vol.5 , pp. 262-269
    • Lovshin, J.A.1    Drucker, D.J.2
  • 11
    • 80054690193 scopus 로고    scopus 로고
    • Four weeks of treatment with liraglutide reduces insulin dose without loss of glycemic control in type 1 diabetic patients with and without residual {beta}-cell function
    • Kielgast U, Krarup T, Holst JJ, et al. Four weeks of treatment with liraglutide reduces insulin dose without loss of glycemic control in type 1 diabetic patients with and without residual {beta}-cell function. Diabetes Care. 2011;34:1463-1468.
    • (2011) Diabetes Care. , vol.34 , pp. 1463-1468
    • Kielgast, U.1    Krarup, T.2    Holst, J.J.3
  • 12
    • 72249103423 scopus 로고    scopus 로고
    • Effects of exenatide alone and in combination with daclizumab on beta-cell function in long-standing type 1 diabetes
    • Rother KI, Spain LM, Wesley RA, et al. Effects of exenatide alone and in combination with daclizumab on beta-cell function in long-standing type 1 diabetes. Diabetes Care. 2009;32:2251-2257.
    • (2009) Diabetes Care. , vol.32 , pp. 2251-2257
    • Rother, K.I.1    Spain, L.M.2    Wesley, R.A.3
  • 13
    • 79959392262 scopus 로고    scopus 로고
    • Liraglutide as additional treatment for type 1 diabetes
    • Varanasi A, Bellini N, Rawal D, et al. Liraglutide as additional treatment for type 1 diabetes. Eur J Endocrinol. 2011;165:77-84.
    • (2011) Eur J Endocrinol. , vol.165 , pp. 77-84
    • Varanasi, A.1    Bellini, N.2    Rawal, D.3
  • 14
    • 64749099781 scopus 로고    scopus 로고
    • Glycemia and cardiovascular disease in type 1 diabetes mellitus
    • Wajchenberg BL, Feitosa AC, Rassi N, et al. Glycemia and cardiovascular disease in type 1 diabetes mellitus. Endocr Pract. 2008;14:912-923.
    • (2008) Endocr Pract. , vol.14 , pp. 912-923
    • Wajchenberg, B.L.1    Feitosa, A.C.2    Rassi, N.3
  • 15
    • 65949122087 scopus 로고    scopus 로고
    • One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: A randomized, controlled trial
    • Bunck MC, Diamant M, Corner A, et al. One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial. Diabetes Care. 2009;32:762-768.
    • (2009) Diabetes Care. , vol.32 , pp. 762-768
    • Bunck, M.C.1    Diamant, M.2    Corner, A.3
  • 16
    • 0036828227 scopus 로고    scopus 로고
    • Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats
    • Farilla L, Hui H, Bertolotto C, et al. Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats. Endocrinology. 2002;143:4397-4408.
    • (2002) Endocrinology. , vol.143 , pp. 4397-4408
    • Farilla, L.1    Hui, H.2    Bertolotto, C.3
  • 17
    • 77952758235 scopus 로고    scopus 로고
    • Effect of glucagon-like peptide-1 on alpha- and beta-cell function in C-peptide-negative type 1 diabetic patients
    • Kielgast U, Asmar M, Madsbad S, et al. Effect of glucagon-like peptide-1 on alpha- and beta-cell function in C-peptide-negative type 1 diabetic patients. J Clin Endocrinol Metab. 2010;95:2492-2496.
    • (2010) J Clin Endocrinol Metab. , vol.95 , pp. 2492-2496
    • Kielgast, U.1    Asmar, M.2    Madsbad, S.3
  • 18
    • 53749089728 scopus 로고    scopus 로고
    • Combination therapy with glucagon-like peptide-1 and gastrin induces beta-cell neogenesis from pancreatic duct cells in human islets transplanted in immunodeficient diabetic mice
    • Suarez-Pinzon WL, Lakey JR, Rabinovitch A. Combination therapy with glucagon-like peptide-1 and gastrin induces beta-cell neogenesis from pancreatic duct cells in human islets transplanted in immunodeficient diabetic mice. Cell Transplant. 2008;17:631-640.
    • (2008) Cell Transplant. , vol.17 , pp. 631-640
    • Suarez-Pinzon, W.L.1    Lakey, J.R.2    Rabinovitch, A.3
  • 19
    • 34547672616 scopus 로고    scopus 로고
    • Continuous stimulation of human glucagon-like peptide-1 (7-36) amide in a mouse model (NOD) delays onset of autoimmune type 1 diabetes
    • Zhang J, Tokui Y, Yamagata K, et al. Continuous stimulation of human glucagon-like peptide-1 (7-36) amide in a mouse model (NOD) delays onset of autoimmune type 1 diabetes. Diabetologia. 2007;50:1900-1909.
    • (2007) Diabetologia. , vol.50 , pp. 1900-1909
    • Zhang, J.1    Tokui, Y.2    Yamagata, K.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.